September 18th 2024
The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.
The mTOR Pathway's Influence on Stenting Choices in Diabetics
November 17th 2015In non-diabetic patients, researchers have shown sirolimus-eluting stents to be more effective than paclitaxel-eluting stents, leading to better clinical outcomes. Some researchers believe that T2DM attenuates the mammalian target of rapamycin (mTOR) signaling pathway. This could influence the choice of stents, and has created a controversy.
Nasal Dry Powder Glucagon Device Is One Step Closer to Approval
November 17th 2015Severe hypoglycemia is a complication of insulin use that occurs in 20% of insulin-treated patients on a monthly basis. A small number of these patients become unconscious or seize as a result of severe hypoglycemia. Hospitals are prepared to intervene, but often in the community, a Good Samaritan needs to reconstitute and injection dry powder formulations of subcutaneous and intramuscular glucagon for unconscious or seizing patients.
Getting Closer to a Reliable Artificial Human Pancreas
November 17th 2015Despite the many glucose monitoring and insulin delivery devices that are available, many diabetics who use them remain uncontrolled and experience hypoglycemia. Researchers dream of the day that drug-device combinations will track diabetics' glucose levels and deliver appropriate insulin dose.
Leptin: 20 Years of Research on Metabolic Health
November 17th 2015Leptin (an adipocyte-secreted hormone) has been an object of observation since 1994. Its levels in the body are roughly proportional to an individual's amount of adipose tissue. It seems to regulate energy homeostasis, decrease energy intake, and increase energy expenditure. From its discovery, researchers hoped that its manipulation could be useful clinically.
Using EMRs to Analyze Diabetes Subtypes
There are many varieties of type 2 diabetes, a new genotype analysis shows. Tracking these genotype variations in common diseases is possible using data from electronic medical records (EMRs), according to researchers at the Icahn School of Medicine at Mount Sinai in New York City.
Type 2 Diabetes ELIXA Trial Update on CV Risk, Stroke, and Mortality
October 30th 2015The much buzzed about Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial has been tracking the medication in patients with type 2 diabetes. An update on the outcomes was provided at the 10th Annual Cardiometabolic Health Congress (CMHC 2015) in Boston, Massachusetts.